Skip to main content
Premium Trial:

Request an Annual Quote

C2i Genomics, NuProbe Global Enter Strategic Alliance for AI-Based Cancer Detection, Monitoring

NEW YORK ─ Cancer diagnostic company C2i Genomics said Wednesday it has entered a strategic alliance with NuProbe Global that leverages C2i's artificial intelligence-based cancer platform and NuProbe's chemistry products and sequencing networks in China and the US.

The deal expands C2i into China, the firm said.

NuProbe, based in Shanghai and Houston, will collaborate with C2i on the development of chemistry and software products to expand traditional whole-genome library preparation to include additional signal enrichment for cancer hotspots, microsatellite instability, and fusions, C2i said.

C2i added that the deal will expand its AI-based cancer detection and monitoring capabilities in the US and China and will combine its AI-based cancer platform with NuProbe's sequencing technology to enable pharmaceutical and diagnostic services.

The combined products will be commercialized in China through the NuProbe sequencing lab network and for the rest of the world with NuProbe's chemistry kit and C2i’s cloud-based cancer intelligence platform. 

Financial and other terms of the agreement were not disclosed.

In June, C2i announced it had inked an agreement with Singapore-based genomic services provider NovogeneAIT Genomics to launch its C2-Intelligence Platform for minimal residual disease detection in Southeast Asia. Further, in July C2i said that it is teaming with healthcare group purchasing organization Premier to make artificial intelligence-enabled cancer detection and monitoring technology available to the 4,000 or so US hospitals in the Premier network.

Meanwhile, in September, NuProbe and Bionano Genomics announced a collaboration whereby NuProbe will integrate its quantitative amplicon sequencing and blocker displacement amplification technologies with Bionano's Saphyr optical genome mapping platform for research and product development.